Interaction Check

This page cannot be displayed because your browser has been configured to disable JavaScript, also known as "Active Scripting".Please change your settings and refresh the page.

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

MultiCheck Results - 18 Interactions

Monitor/Modify Tx
BiDil (isosorbide dinitrate/ hydralazine) + Hyzaar (losartan/ hydrochlorothiazide)
Monitor/Modify Tx hydralazine + hydrochlorothiazide monitor BP: combo may incr. risk of severe hypotension (additive effects) hydralazine + losartan monitor BP: combo may incr. risk of severe hypotension (additive effects) isosorbide dinitrate + hydrochlorothiazide monitor BP: combo may incr. risk of hypotension (additive effects) isosorbide dinitrate + losartan monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
BiDil (isosorbide dinitrate/ hydralazine) + Lutera (levonorgestrel/ ethinyl estradiol)
Monitor/Modify Tx hydralazine + ethinyl estradiol (contraceptive) monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
BiDil (isosorbide dinitrate/ hydralazine) + Synjardy XR (empagliflozin/ metformin)
Monitor/Modify Tx hydralazine + empagliflozin monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects) isosorbide dinitrate + empagliflozin monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Hyzaar (losartan/ hydrochlorothiazide) + Lutera (levonorgestrel/ ethinyl estradiol)
Monitor/Modify Tx hydrochlorothiazide + ethinyl estradiol (contraceptive) monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) losartan + ethinyl estradiol (contraceptive) monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Hyzaar (losartan/ hydrochlorothiazide) + Synjardy XR (empagliflozin/ metformin)
Monitor/Modify Tx hydrochlorothiazide + empagliflozin monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects) hydrochlorothiazide + metformin monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) losartan + empagliflozin monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Lutera (levonorgestrel/ ethinyl estradiol) + Synjardy XR (empagliflozin/ metformin)
Monitor/Modify Tx ethinyl estradiol (contraceptive) + empagliflozin monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) ethinyl estradiol (contraceptive) + metformin monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) levonorgestrel (contraceptive) + empagliflozin monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects) levonorgestrel (contraceptive) + metformin monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Pegasys (peginterferon alfa 2a) + Synjardy XR (empagliflozin/ metformin)
Monitor/Modify Tx peginterferon alfa 2a + empagliflozin monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (antagonistic effects, additive effects) peginterferon alfa 2a + metformin monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (additive effects, antagonistic effects)
Additional Considerations
peginterferon alfa 2a in Pegasys
when used to treat HCV, caution advised with narrow therapeutic index drugs extensively metabolized in the liver; viral eradication may improve hepatic metabolic function, decr. levels, efficacy of concomitant drugs